| Uncertainty in the timing of origin of animals and the limits of precision in molecular timescales M Dos Reis, Y Thawornwattana, K Angelis, MJ Telford, PCJ Donoghue, ... Current biology 25 (22), 2939-2950, 2015 | 464 | 2015 |
| Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 … JM Llibre, CC Hung, C Brinson, F Castelli, PM Girard, LP Kahl, EA Blair, ... The Lancet 391 (10123), 839-849, 2018 | 427 | 2018 |
| Efficacy and safety of dolutegravir–rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 … M Aboud, C Orkin, D Podzamczer, JR Bogner, D Baker, ... The lancet HIV 6 (9), e576-e587, 2019 | 132 | 2019 |
| Dolutegravir-based antiretroviral therapy for patients coinfected with tuberculosis and human immunodeficiency virus: a multicenter, noncomparative, open-label, randomized trial KE Dooley, R Kaplan, N Mwelase, B Grinsztejn, E Ticona, M Lacerda, ... Clinical Infectious Diseases 70 (4), 549-556, 2020 | 103 | 2020 |
| The impact of ancestral population size and incomplete lineage sorting on Bayesian estimation of species divergence times K Angelis, M Dos Reis Current Zoology 61 (5), 874-885, 2015 | 86 | 2015 |
| The global spread of HIV-1 subtype B epidemic G Magiorkinis, K Angelis, I Mamais, A Katzourakis, A Hatzakis, J Albert, ... Infection, genetics and evolution 46, 169-179, 2016 | 79 | 2016 |
| Global dispersal pattern of HIV type 1 subtype CRF01_AE: a genetic trace of human mobility related to heterosexual sexual activities centralized in Southeast Asia K Angelis, J Albert, I Mamais, G Magiorkinis, A Hatzakis, O Hamouda, ... The Journal of infectious diseases 211 (11), 1735-1744, 2015 | 67 | 2015 |
| Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health GA McComsey, S Lupo, D Parks, MC Poggio, J De Wet, LP Kahl, ... Aids 32 (4), 477-485, 2018 | 65 | 2018 |
| Brief report: durable suppression and low rate of virologic failure 3 years after switch to dolutegravir+ rilpivirine 2-drug regimen: 148-week results from the SWORD-1 and … J Van Wyk, C Orkin, R Rubio, J Bogner, D Baker, MA Khuong-Josses, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 85 (3), 325-330, 2020 | 51 | 2020 |
| Dolutegravir/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV CP Rolle, M Berhe, T Singh, R Ortiz, A Wurapa, M Ramgopal, PA Leone, ... Aids 35 (12), 1957-1965, 2021 | 49 | 2021 |
| Dating the origin of hepatitis B virus reveals higher substitution rate and adaptation on the branch leading to F/H genotypes D Paraskevis, K Angelis, G Magiorkinis, E Kostaki, SYW Ho, A Hatzakis Molecular Phylogenetics and Evolution 93, 44-54, 2015 | 47 | 2015 |
| Unravelling the history of hepatitis B virus genotypes A and D infection using a full-genome phylogenetic and phylogeographic approach EG Kostaki, T Karamitros, G Stefanou, I Mamais, K Angelis, A Hatzakis, ... Elife 7, e36709, 2018 | 40 | 2018 |
| An evaluation of different partitioning strategies for Bayesian estimation of species divergence times K Angelis, S Álvarez-Carretero, M Dos Reis, Z Yang Systematic Biology 67 (1), 61-77, 2018 | 39 | 2018 |
| Safety and efficacy of dolutegravir-based ART in TB/HIV coinfected adults at week 24 K Dooley, R Kaplan, N Mwelase, B Grinsztejn, E Ticona, M Lacerda, ... 25th Conference on Retroviruses and Opportunistic Infections (CROI), 2018 | 30 | 2018 |
| Dolutegravir-based antiretroviral therapy for patients co-infected with tuberculosis and HIV: a multicenter, noncomparative, open-label, randomized trial KE Dooley, R Kaplan, N Mwelase, B Grinsztejn, E Ticona, M Lacerda, ... Oxford University Press, 2019 | 25 | 2019 |
| The impact of Measles-Rubella vaccination on the morbidity and mortality from Congenital Rubella Syndrome in 92 countries E Vynnycky, P Timoleon, K Angelis Human Vaccines & Immunotherapeutics 15 (2), 309-316, 2018 | 20 | 2018 |
| Sustained virologic suppression with dolutegravir/lamivudine in a test-and-treat setting through 48 weeks CP Rolle, M Berhe, T Singh, R Ortiz, A Wurapa, M Ramgopal, ... Open forum infectious diseases 10 (3), ofad101, 2023 | 19 | 2023 |
| Bayesian estimation of nonsynonymous/synonymous rate ratios for pairwise sequence comparisons K Angelis, M Dos Reis, Z Yang Molecular Biology and Evolution 31 (7), 1902-1913, 2014 | 17 | 2014 |
| International Study of Patients with HIV on Rifampicin ING study group. Dolutegravir-based antiretroviral therapy for patients coinfected with tuberculosis and human … KE Dooley, R Kaplan, N Mwelase, B Grinsztejn, E Ticona, M Lacerda, ... Clin Infect Dis 70 (4), 549-556, 2020 | 15 | 2020 |
| Durable suppression and low rate of virologic failures 3 years after switch to DTG+ RPV 2DRug Regimen: SWORD 1 and 2 Studies J van Wyk, C Orkin, R Rubio, J Bogner, D Baker, MA Khuong-Josses, ... 25th Annual Conference of the British HIV Association, 2-5, 2019 | 9 | 2019 |